Utilizing the SKG mouse model—characterized by peripheral arthritis, enthesitis, and spondylitis resembling human SpA [30]—we have demonstrated that anti-VEGF-A therapy targets core pathological features of the disease. This evidence concerns the gene VEGFA and enthesitis.